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ABSTRACT
BACKGROUND: Crohn’s disease (CD) is an inflammatory bowel disease (IBD) and has been
associated with Mycobacterium avium subspecies paratuberculosis (MAP). MAP has been
detected in stool, tissue and blood samples from patients with CD. Gamma interferon (γ-IFN) is
an inflammatory cytokine that plays a crucial role in killing intracellular pathogens like MAP,
and its receptor (IFNGR1) mutations cause immunodeficiency and severe disseminated
mycobacterial infections. The role of MAP in association with IFNGR1 mutation in CD patients
have not been investigated.
METHODS: In this study, we investigated blood samples of 79 human subjects for MAP
infection in association with IFNGR1 gene dysfunction. Samples were divided into 22 CD,
6 Ulcerative colitis (UC), 32 normal healthy and 19 non-inflammatory bowel disease
(NIBD). Five variants of IFNGR1 single nucleotide polymorphisms (SNP) were
investigated using Taqman Genotyping assay, then IFNGR1 expression measured by RTPCR and serum IFNGR1 and -IFN levels were measured using ELISA. MAP infection
was detected using nested PCR

RESULTS: Among 28 IBD patients, 4/6 (66.67%) of UC and 18/22 (81.82%) of CD are tested
positive for at least one SNP homozygous minor form compared to 21.88% and 47.37%% in 32
healthy and 19 NIBD (P <0.05). IFNGR1 gene expression was downregulated 1.4-fold in IBD
patients (P =0.07) and 1.7-fold downregulated in MAP positive IBD patients compared to MAP
negative IBD patients (P=0.06). Serum IFNGR1 protein levels were downregulated 1.53-fold in
IBD patients compared to normal, and 1.4-fold downregulated in MAP positive IBD patients
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compared to MAP negative IBD patients. MAP infection is more common in rs2234711 SNP
positive patients (5/7 =71.42%) (P<0.05). Serum -IFN levels were not elevated in both groups

CONCLUSION: IFNGR1 SNP’s, MAP infection and IFNGR1 downregulation were found in
higher incidence in IBD, suggesting role of IFNGR1 in susceptibility of MAP infection in IBD
patients.
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CHAPTER ONE: INTRODUCTION
Crohn’s Disease
Crohn’s disease (CD) is a chronic relapsing inflammatory disease of gastrointestinal tract
occurring most commonly in Europe and Northern America[1]. Currently in USA, as per Centre
of Disease Prevention and Control (CDC), 1 to 1.3 million of people are suffering from
inflammatory bowel disease. 2.5 million of people in Europe are also estimated to have IBD and
the prevalence is rising in newly industrialized countries such as Asia, South America and
Middle East. CD is usually diagnosed early in adulthood and it keeps remising and relapsing
throughout life, hence the prevalence keeps rising. CD adds significant burden to global
healthcare because of high cost of therapeutic drugs and prolonged disease duration, its effects
on quality of life and career impediments.
CD, together with ulcerative colitis, forms two major categories of Inflammatory Bowel
Diseases (IBD). However, CD is different from ulcerative colitis in that CD affects the entire
gastrointestinal tract from mouth to perianal area, and it affects the entire mucosal thickness.
Affected patients suffer from chronic relapsing episodes of diarrhea, abdominal pain, rectal
bleeding, fever and weight loss [2].
There is no cure for CD so far and treatment for it focuses on anti-inflammatory drugs,
immunosuppressive drugs, and biological agents that inhibit the functions of inflammatory
cytokines. Antibiotics have been proved to be beneficial in treatment of CD[3].

Pathogenesis of Crohn’s Disease
The etiology of CD has been much debated. Defective innate and adaptive immune response,
genetic mutations, environmental factors, alterations in normal intestinal flora proportions,
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several infectious agents including Mycobacterium avium subspecies paratuberculosis (MAP)
have been suggested to play a role in causation of Crohn’s disease [4]. Development of abnormal
immune responses in Th1 and IL-17 producing Th17 responses are predominately observed in
pathogenesis of CD[5]. Activation of macrophages and dendritic cells stimulates secretion of
inflammatory cytokines gamma interferon (INF-γ), IL-1, IL-6 and IL-23 and results in mucosal
inflammation and skip lesions.
Many genetic mutations have been proved to be associated with CD incidence as well.
Variations of genes associated with immune functions such as ATG16L1, IRGM, NOD2 and
IL23R have been shown to be associated with increased risk of CD[6-8]. Genetic variations of
PTPN2 and PTPN 22 has significance in pathogenesis of Crohn’s disease too[9]. Environmental
factors such as smoking, oral contraceptives, diet, vaccinations and childhood hygiene have been
suggested to play a role in CD[10]. In this study, we screened gene expression of 30,000 human
genes using DNA microarray technique to look for genes that are differentially expressed in IBD
patients compared to normal controls.
The role of microbes in etiology of CD have been widely investigated by researchers. Adherentinvasive Escherichia coli, Pseudomonas species, Listeria monocytogenes, Enterococcus fecalis,
Klebsiella pneumoniae, Mycoplasma species and Saccharomyces cerevisiae have shown
association with CD[11]. MAP have been the most intensely investigated microbe because of its
causation of CD-like chronic granulomatous gastrointestinal inflammatory disease called Johne’s
disease in ruminants. Our Lab focuses on establishing the role of MAP in the etiology of
Crohn’s disease.
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Mycobacterium avium paratuberculosis (MAP) And Crohn’s Disease (CD)
Mycobaterium avium subspecies paratuberculosis (MAP) is an intracellular pathogenic
bacterium and an acid-fast bacillus. It is the causative agent for Johne’s disease in cattle and
there has been extensive evidence that suggests it is causal agent of CD as well. The clinical
features of Johne’s disease closely resemble CD in human. Symptoms include fever, abdominal
pain, diarrhea and perianal fistulas. Furthermore, pathology findings of Johne's disease such as
granulomatous ileitis, bowel inflammation and ulcerations have been comparable to those of
CD[12]. MAP has been detected in milk secreted from infected cattle and shown to survive
pasteurization process depending on types of strain and concentration in the milk, hence
predisposing high infection rate in human[13]. It has been isolated from blood, intestinal tissue
and breast milk from CD patients[14, 15].
MAP infection could be detected in human by acid-fast staining and microscopy, detection of
serum antibodies using ELISA, cultures using solid medium like Löwenstein- Jensen media or
liquid medium with automated incubation and reading system like BACTEC MGIT 960 system.
However, the most specific method of detection of MAP in human is proved to be amplification
of IS900 gene sequence specific to MAP using nested PCR technique[16]. Several researchers
have reported increased detection rates of MAP in CD and genetically susceptible individuals
compared to normal healthy humans but wide-spread population studies still need to be done to
determine the prevalence of MAP infection in human[16-18].
Our lab has isolated MAP from blood, intestinal biopsy and breastmilk from CD patients and we
have published several papers establishing association of MAP with CD[14, 15, 19-22].
Currently, our lab collaborated with RedHill Biopharma Ltd to run a Phase III clinical trial,
RHB104, an oral antibiotics combination therapy against MAP on CD patients[23]. In this
3

project, we investigated the role of gamma interferon receptor subunit 1, IFNGR1, mutation
increasing susceptibility to MAP infection in CD patients.
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CHAPTER TWO: ROLE OF IFNGR1 IN CAUSING SUSCEPTIBILITY TO
MAP INFECTION IN CD
Summary
Crohn’s disease has multiple factors in etiology, among which infection and genetic
predisposition are of utmost importance. MAP has been shown to play a role in CD by several
studies[17, 24, 25]. In this study, we researched 79 human subjects including 22 CD patients and
we identified that four IFNGR1 SNP’s are associated with defective immune response against
mycobacterial infections, to be more common in CD patients and their gene expressions
downregulated. Furthermore, these SNP positive patients have higher MAP infection rate.
Hence, this study demonstrated a new genetic predisposition that make individuals susceptible to
MAP infection and CD development.

Introduction
CD patients have elevated levels of pro-inflammatory cytokines including interferon gamma (γIFN) and tumour necrosis factor alpha (TNF-α). Interestingly, γ-IFN is crucial to defend against
intracellular pathogens. Like in tuberculosis, it initiates granuloma formation which supports a
possible MAP association with CD. Fais. S. et al have reported an elevated γ-IFN response in
peripheral lymphocytes from CD patients, suggesting prior sensitization with mycobacterial
antigens[25]. IFNGR1, which is the major subunit of the two subunits of γ-IFN receptor, have
shown mutations, single nucleotide polymorphisms (SNP), deletions and they all have been
identified to cause immunodeficiency and susceptibility to various infections including
Mycobacterium tuberculosis, atypical mycobacteria and intracellular organisms such as
Salmonella, Malaria, and Leishmania [26-29]. No studies have investigated the role of IFNGR1
in CD.
5

Differentially expressed genes in CD and UC
Previously in our lab, Dr. Romero Claudia performed DNA microarray technique to screen
for differentially expressed genes in 2 CD and 1 UC patients compared to 8 healthy
individuals. We found that 17% (5630 genes) were differentially expressed in both IBD
disorders (Figure 1). Most of these genes belong to four biological functions classified as
cellular processes (38%) physiological processes (26%), intracellular genes (18%), and
genes involved in metabolism (18%). 238 genes that are differentially expressed belong to
immune response processes. As shown in Table 1 and 2, seven genes expression were
different in both UC and CD compared to normal subjects and eight genes were
differentially expressed in either UC or CD. Among them, IFNGR1 will be focused in our
study because CD and UC are diseases arisen by abnormal immune response mechanisms

Mechanism of IFNGR1 mutation
γ-IFN is secreted by Th1 lymphocytes, natural killer cells and antigen presenting cells. Its
secretion is initiated by mycobacterial cell wall components such as purified protein derivative
(PPD), and peptidoglycan[30]. It induces up-regulation of MHC class 1 cell surface receptors,
hence increasing potential for cytotoxic T cell recognition and destruction of host cells infected
with MAP. γ-IFN produced from Th1 cells promotes antigen presentation and IL-1 and IL-12
release from macrophages, hence resulting in further activation of Th1 cells, further γ-IFN
production and aggregation of Th1 cells around macrophages and granuloma formation[31].
Ultimately it results in intracellular bacteria killing. γ-IFN receptor is a heterodimeric type II
cytokine receptor and is composed of IFNGR1 and IFNGR2. Two subunits of IFNGR1 binds to
ligand and two more subunits of IFNGR2 carry out signal transduction via JAK/STAT pathway.
IFNGR1 is also known as Cluster of Differentiation 119 (CD119). It has two forms, soluble form
6

and classic membrane bound form. IFNGR1 gene is mapped to human chromosome 6 at region
6q23–6q24[32]. Inactivating mutations in IFNGR1 have shown defective defense against
intracellular pathogens in mouse models[33]. In human counterparts, significant clinical
manifestations have been reported too. Small deletions in coding regions of IFNGR1 causes
dominant susceptibility to non-virulent mycobacterial infections in children[34]. These children
are shown to suffer from disseminated and fatal mycobacterial infections with Bacillus CalmetteGuérin (BCG) vaccination which is made from Mycobacterium bovis. Some children with
IFNGR1 autosomal recessive pattern mutations suffer from a condition called Familial Atypical
Mycobacteriosis; an immunodeficiency that predispose them to infection of various atypical
mycobacteria (M. fortuitum, M. chelonei, and two strains of M. avium), and prolonged
salmonellosis [26-28, 35-37].
Single nucleotide polymorphisms (SNP) are variations in a single nucleotide at a specific
position of a gene. Each variation is present to some extent in the population and phenotypic
expression can vary from benign to genetic susceptibility to disease, higher risk of infections,
different response to therapeutic regimes and severity of a disease. SNP rs2234711 is located at
transcription factor AP4 binding site of IFNGR1 gene while rs7749390 is at exon-intron splicing
site. Association studies have shown that both SNP are associated with increased risk for
Mycobacterium tuberculosis infection in Chinese Han population and contributes to increased
susceptibility to post kala-azar dermal leishmaniasis in Sudanese population[28, 38]. Marker
rs7749390 is shown to be associated with Eczema herpeticum, a Herpes Simplex virus infection
to pre-existing atopic dermatitis[39].
However, the role of IFNGR1 mutations and SNP on susceptibility to MAP infection or their
incidence in inflammatory bowel disease patients and autoimmune disease patients has never
7

been investigated. In this study, we investigated the presence of 5 SNP’s (rs1327474, rs1327475,
rs2234711, rs7749390, rs3799488) in Crohn’s disease patients and their status of MAP infection
compared to normal healthy controls. Their effect on IFNGR1 gene expression and serum level
of γ-IFN were also investigated. From this study, we hope to identify novel therapeutic targets
for Crohn’s disease patients by uncovering more underlying factors in disease causation.

Materials and Methods
Detection of IFNGR1 SNP type and frequency using Taqman
EDTA blood from IRB approved patients recruited from Univeristy of Central Florida
Health, and Digestive and Liver Center of Florida were collected and a total of 79 patients
including 22 CD, 6 UC, 14 healthy subjects and 16 NIBD are analysed for the presence of
SNP. Taqman SNP Genotyping Assay (Thermo fisher Scientific) were used for 5 IFNGR1
SNP’s rs1327474, rs1327475, rs2234711, rs7749390 and rs3799488. Assay IDs, their
location on IFNGR1 gene and nucleotide sequencing are shown in Table 3. 1ml of whole
blood samples were stored at -20C and sent to University of Florida for genotyping analysis.
Taqman® Genotyping Assay utilizes 5’ exonuclease activity of Taq DNA polymerase. It
includes two oligonucleotide Taqman Probes each specific to one allele of the target gene
that have fluorescence reporter dye on 5’ end and non-fluorescent quencher (NFQ) with
minor groove binder (MGB) at 3’end. One probe is labelled with VIC dye and detects allele
1 sequence, another is labelled with FAM dye and detects the allele 2 sequence. In its
unbound form, fluorescent signal at 5’ end is quenched by 3’end quencher due to proximity.
When the probe binds to the target allele, 5’ fluorescence is hybridized by 5’exonuclease
activity of Taq Polymerase and emits fluorescence [40](Figure 2).
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Taqman SNP genotyping was done by adding 1 to 20ng of purified gDNA sample extracted
from whole blood, 40X Taqman Genotyping Assay diluted to 20X working stock, and 2X
Taqman Universal PCR Mastermix. PCR reaction was run in thermal cycler with AmpliTaq
Gold Enzyme Activation step of 10 mins holding at 950C, followed by 40 cycles of PCR (15
seconds denaturation at 920C and 1 minute annealing/extension at 600C). The fluorescence
was picked up by the machine and the data is analyzed to detect presence of homozygous
major allele, homozygous minor allele or heterozygous state.

Measurement of IFNGR1 gene expression
Measurement of IFNGR1 expression includes 3 steps (1) RNA extraction (2) cDNA
synthesis and (3) Real Time quantitative PCR analysis.
RNA extraction was done using Trizol® Reagent (Invitrogen) using manufacturer’s protocol.
1 ml of Trizol® Reagent was used to extract RNA from buffy coat from 1ml of blood. RNA
was separated from DNA and proteins by adding choloroform. Supernatant containing RNA
was centrifuged and RNA pallet was washed with 100% propanol and then again with 75%
ethanol. Finally RNA pallet was suspended in RNase free water treated by Diethyl
Pyrocarbonate (≥97% (NMR) Sigma-Aldrich) and heated at 55-60oC for 15 minutes for
denaturation. RNA quality is accessed by running 6% urea-polyacrylamide gel. RNA
concentration is measured by NanoDrop ND 1000 Spectrophotometer (Thermo Fisher).
cDNA was synthesized using iScriptTM Reverse Transcription Supermix for RT-qPCR kit
(BioRad) per manufacturer’s protocol. 4uL of 5X RT supermix is added to 600ng of
extracted total RNA and DEPC treated sterile water is added to make 20 ul reaction. Then the
complete reaction mix is incubated in thermal cycler for 5 minutes at 25oC for priming, 20
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mins at 46oC for reverse transcription, 1 min at 95oC for reverse transcriptase activation. The
cDNA synthesized is stored at -20oC for further processing.
1ul of cDNA was added into 10ul of Fast SYBR® Green Supermix (Applied Biosystems)
and 1ul of PrimePCR assay for IFNGR1. Then, water was added to make 20 ul reaction.
The primers used were from PrimePCR SYBR Green assay IFNGR1, Human, unique assay
ID: qHsaCID0013339 (Bio-rad). PrimePCR Template for SYBR Green assay: IFNGR1,
Human(Bio-rad) was used as positive control reaction to check melting temperature and
melting curve.
Human 18S ribosome was used as control reaction, reactions are prepared as above using
specific primers. Applied Biosystems 7500 real time PCR system was used for qPCR
analysis with manufacturer recommended protocol of stage 1: 20 seconds holding at 95oC,
stage 2: 40 cycles of 3 seconds denaturation at 950C, 30 seconds of annealing/extension at
600C, and at annealing/extension stage, fluorescence was captured. Dissociation stage was
run from 950C to 600C, with 15 seconds increments, and melting temperature for IFNGR1
gene was 730C in accordance with positive template control reaction. The size of amplicon is
84 base pairs.
Ct value was captured and ∆Ct value was calculated and compared with normal controls.

Measurement of IFNGR1 protein level in serum
We used Human IFNGR1 ELISA kit (RayBiotech) for detection of IFNGR1 soluble form in
serum. Reagents and standards were prepared according to manufacturer’s protocol and 100
ul of serum collected from blood samples were added to wells, then incubated for 2.5 hours
at RT. Then they were washed with 300 ul of 1X wash solution for 4 times and blotted
10

against clean paper towels. 100 ul of 1X biotinylated antibody was added, incubated for 1
hour at RT and washed. Then, 100 ul of streptovidin solution was added, incubated for 45
minutes and washed. Finally, 100 ul of TMB one-step substrate reagent was added, incubated
for 30 mins, then stop solution was added and read immediately at 450 nm. Standard curve
was created using software and results were calculated from the standard curve obtained.

Measurement of γ-IFN protein level in serum
γ-IFN was measured in serum using γ-IFN ELISA kit (Thermo Fischer) following
manufacturer’s protocol.

Detection of MAP infection
Nested polymerase chain reaction (PCR) and culturing in BACTEC media for sensitivity and
specificity of MAP detection was used. Insertion sequence IS900 is specific only to MAP
strains infecting human. DNA extraction was done from extracted buffy coats from whole
blood using DNAzol® BD Reagent (Invitrogen). Then, nested PCR technique with primers
P90 and P91 (P90 5’ GTT CGG GGC CGT CGC TTA GG 3’ and P91 5’ GAG GTC GAT
CGC CCA CGT GA 3’) for first PCR cycle and primers AV1 and AV2 (AV1 5’ ATG TGG
TTG CTG TGT TGG ATG G 3’ and AV2 5’ CCG CCG CAA TCA ACT CCA G 3’) for
second PCR cycle were used. This increases the specificity of PCR reaction for MAP.
Finally, the PCR products were electrophoresed on 2.5% agarose gel and stained with
ethidium bromide for visualization. 298 base pairs band in gel were considered MAP
positive.
The positive controls we used in our experiments were MAP bacteria grown in Mycobacteria
Growth Indicator Tubes (MGIT). MGIT contains Middlebrook 7H9 broth base for culturing
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of Mycobacteria and a fluorescent compound is embedded in the silicon on the bottom of the
tube. We use BBLTM MGITTM tubes (Becton, Dickinson and Company). BACTECTM
MGITTM Growth Supplement (BD) and Mycobactin J (BD) is added to help grow MAP.
Mycobactin J is the iron-binding and transporting factor that is necessary for in vitro growth
of MAP. The extracted buffy coat is dissolved in 200 ul of TE buffer and added into prepared
MGIT tube and cultured in BACTECTM MGITTM 320 System at 37oC. The system checks for
fluorescence every 60 minutes and 105 to 106 colonies forming units per milliliter (CFU/ml)
is reported as positive. The culture tubes that shows no growth for a minimum of 42 days are
regarded as negative. The BACTECTM MGITTM 320 technology is superior to traditional
culture medias in that it is more sensitive and less time consuming.

Results
Investigation for prevalence of IFNGR1 SNP’s
We detected presence of five IFNGR1 SNP’s in 32 healthy subjects, 28 IBD patients
including 6 UC patients, 22 CD patients. As controls, we additionally investigated SNP’s
presence in 19 non IBD (NIBD) patients. NIBD patients are patients they have some other
diagnoses other than CD or UC. For example, some patients have RA, while others have
type 1 or type 2 diabetes, and/or irritable bowel syndrome. Five SNP’s investigated are
rs1327474, rs1327475, rs2234711, rs7749390 and rs3799488.
As seen in Figure 3, rs1327474 is tested positive for homozygous in minor allele in 2 out
of 14 normal subjects (14.3%), 0% in NIBD, 4 out of 21 CD (19%), and 1 out of 6 UC
(16.7%). CD and UC are combined to be IBD group, so the prevalence of IBD groups for
rs1327474 is 5/27 (18.5%). Rs1327475 is tested homozygous minor in none of the samples
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tested. Hence prevalence of rs1327474 and rs1327474 is relatively same in all groups.
Homozygous minor allele status for rs2234711 is found in 5 out of 32 healthy (15.6%), 3
out of 19 NICD (15.8%), 5 out of 22 CD (22.7%) and 1 out of 6 UC (16.7%), in IBD
group, it is 21.4%. Rs7749390 is seen homozygous minor allele positive in 6/32 normal
(18.8%), 6 NIBD (31.6%), 12 CD (54.5%) and 3 UC (50%), in combined IBD group, it
becomes 53.6%. Similarly, homozygous minor allele for rs3799488 is found in 2 CD
(9.1%) and 0 UC, in IBD it is 3.6% compared to 0% in both healthy and NIBD group. We
can see that homozygous minor status is clearly more common in CD and UC patients than
healthy and NIBD patients for rs2234711, rs7749390 and rs3799488 and it is significant in
rs7749390 (P <0.05).
However, heterozygous status for major and minor allele has a different distribution (Figure
4). Prevalence for heterozygous alleles is higher in healthy and NIBD population than CD
and UC position in most SNP’s. Heterozygous rs1327474 is seen in 7 out of 14 healthy
(50%), 8 out of 16 NIBD (50%), and 10 out of 21 CD (47.62%) and 3 out of 6UC (50%),
bringing IBD prevalence to 48.15% against 50% in both healthy and NIBD group. So, as
with homozygous minor rs 1327474, there is no difference in prevalence of its
heterozygous status. Rs1327475 heterozygous status is seen only in one healthy subject and
this is the only minor allele seen in all samples tested. Both rs2234711 and rs7749390 are
seen in 17 out of 32 healthy, 8 out of 19 NIBD, 3 out of 22 CD (13.6%) and 2 out of 6 UC
(33.3%). Hence IBD incidence is 17.9 % compared to 53.1% healthy and 42.1% NIBD.
Rs3799488 heterozygosity is seen in 6/32 (18.6%) healthy and 3/19 (15.8%) NIBD,
whereas in IBD patients, there is 2/22 (9.1%) in CD and 1/6 UC (16.7%) respectively.
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Overall speaking, out of 32 healthy, 7 people (21.9 %) and 9 out of 19 NIBD (47.4%) have
at least one SNP homozygous minor allele present. However, in IBD group, 4/6 (66.7%)
UC and 18/22 (81.8%) CD has at least one SNP homozygous minor allele present (Figure
5). So, incidence of homozygous minor alleles of 5 SNP’s under the study is much more
common in both CD and UC (P<0.05).

Measurement of IFNGR1 gene expression
We measured gene expression of IFNGR1 gene using RT-PCR in 30 healthy, 14 NIBD and
54 IBD samples. Among them, 24 healthy, 14 NIBD, 24 IBD were detected for presence of
MAP and 30 healthy, 14 NIBD and 23 IBD were detected for the presence of SNP. The
gene expression levels were reported as mean of (2 (-∆CT) x 1000) ± 95% CI. Mean of
healthy group is 5.3 ± 2.4 compared to 4.5± 0.9 of NIBD and 3.8± 0.9 of IBD. IBD
samples were 1.4-fold downregulated (P=0.07) whereas NIBD samples were 1.2-fold
downregulated (P = 0.32) (Table 4). But we classified them into MAP positive and MAP
negative in each group (Table 5), as well as SNP positive and SNP negative in each group
(Table 6) and analyzed them separately. Both SNP and MAP causes downregulation in
IBD group, 1.5-fold in presence of SNP (P =0.1) and 1.7-fold in presence of MAP (P =
0.08). The group that has co-existence of SNP and MAP together still causes 1.7-fold
downregulation. (P =0.08).

Measurement of IFNGR1 protein level in serum
We carried out ELISA to measure the amount of IFNGR1 protein in serum in 6 healthy, 9
NIBD and 24 IBD patients, then classified them into SNP positive and negative groups and
compared against each other. Mean of IFNGR1 proteins levels along with 95% CI is found
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as follows. Healthy group has 810.8 ± 1024.5 pg/ml whereas IBD group has 530.3 ± 190.5
pg/ml and NIBD group is 502.7 ± 263.2 pg/ml. IBD group is 1.53-fold lower (P = 0.15) and
NIBD group is 1.61-fold lower (P = 0.21) than healthy group (Table 7) Considering MAP
infection status, it causes 1.4-fold downregulation in both IBD and healthy group (P = 0.5)
(Table 8). The presence of SNP and MAP together causes 1.42-fold lower levels of
IFNGR1 protein in healthy, 2.14-fold in NIBD and 1.51-fold in IBD (Table 9). However,
presence of SNP alone doesn’t appear to lower IFNGR1 levels. Healthy subjects have 1.3fold higher levels, NIBD subjects have similar levels and IBD patients have 1.1 times
higher levels (Table 10).

Measurement of -IFN protein level in serum
In 2005, we tested 5 controls for serum --IFN levels using ELISA and 7 IBD as
preliminary studies. Average values are 6.7 ± 4.1 pg/ml in healthy compared to 77.7
±123.1 pg/ml. IBD samples are 11.6-fold upregulated compared to control samples
(P>0.1).
In 2017, we analyzed 29 controls versus 25 IBD. Except for one outlier in healthy group
that has elevated --IFN level of 364.6 pg/ml, all other samples in both groups show
either low or undetectable levels of --IFN. Mean value for control group is 0.7± 1.1
pg/ml while IBD group mean serum --IFN shows 0.3±0.7 pg/ml. Thus, there is no
significant elevation of serum --IFN anymore in 2017 in IBD group, as seen in figure 6.
We assume these changes are due to wide-spread use of biological agents which block
functions and secretion of cytokines.
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Detection of MAP infection
MAP infection is detected by either nested PCR from buffy coats extracted from freshly
drawn blood, or nested PCR from MAP cultures done from buffy coats. 4 out of 32
healthy are MAP positive (12.5%) as well as 6/19 of NIBD (18.8%). In IBD group, 11 out
of 28 CD are MAP positive (34.4%). We see from the data that MAP incidence is more
common in IBD group compared to healthy (P <0.05) (Figure 7).
Of the MAP positive patients, 1/4 healthy (25%) subjects in healthy and 2/3 (33.3%)
NIBD has at least one homozygous minor allele SNP. In IBD group, 9 out of 11 MAP
positive patients have at least one homozygous minor allele SNP (81.8%), making it
clear that presence of SNP makes an individual more prone to MAP infection in IBD
patients (P<0.05) (Figure 8).

Co-existence of SNP and MAP infection
In homozygous minor allele SNP’s, none but 1 out of 4 CD (25%) in rs1327474 is associated
with MAP. Rs1327475 has no homozygous minor alleles detected. For rs2234711, none of 1
healthy and 3 NIBD patients that has SNP positive has MAP infection. However, 1 UC with SNP
has MAP detected (100%), 4 out of 6 CD is infected with MAP (66.67%). Therefore, we can see
that MAP detection is more common in IBD patients (71.4%) compared to 0% in healthy and
NIBD. Rs7749390 homozygous minor SNPs positive subjects were tested MAP positive in 1/5
(20%) of healthy, 2/6 (33.33%) of NIBD, and 1/3 (33.33%) in UC and 3/12 (25%) in CD. For
rs3799488, only 2 CD has SNP positive for homozygous minor status out of all subjects and 1
(50%) is associated with MAP. Hence, we can see that MAP infection is more common in
rs2234711 homozygous minor patients (P <0.05), though MAP infection is not significantly
different in rs1327474 and rs774939 (Table 11).
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Odds ratio for having at least one SNP in IBD group is 13.1 times more than control
group. (P <0.05) (95% confidence interval = 3.8 to 44.9). Odds ratio for presence of MAP
in the blood is also 4.5 times higher in IBD patients (P <0.05) (95% CI = 1.24 to 16.5).
Calculations using Spearman’s rho test show that presence of MAP and SNP are positively
correlated with rho value of 1. (P <0.05). Presence of MAP and gene expression are
weakly negatively correlated, rho = -0.125. (P = 0.234).

Discussion
Investigation for prevalence of IFNGR1 SNP’s
As seen in Table 1, all 5 SNP’s investigated in this study are somehow related with
susceptibility to Mycobacterium tuberculosis, Helicobacter pylori, parasites such as
Leishmania and Schistosoma, and viral infections such as Herpes simplex in different
ethnicities and population. But our study is the first to investigate the role of IFNGR1
SNPs in IBD patients, as well as role of IFNGR1 SNPs in susceptibility to MAP infection.
As seen in our data, the incidence of these homozygous minor SNPs is higher in IBD
patients, hence suggesting the role of IFNGR1 mutations in the causation of CD. Four
SNPs, rs1327474, rs2234711, rs7749390, rs3799488 have been associated with
Mycobacterium tuberculosis susceptibility in literature and in our study, those SNPs are
also found in higher incidence in CD patients. Rs7749390 is showing statistical
significance (P <0.05) and larger sample size is needed to show significance in other SNPs
too. We also found statistical significance when all SNPs are analyzed together that IBD
patients are 13.1 times more likely to have underlying IFNGR1 homozygous minor SNPs
compared to other NIBD and healthy subjects. MAP infection is seen in higher incidence
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with patients with homozygous minor SNP. Thus, it shows that IFNGR1 SNPs are
contributing to susceptibility of MAP infection in CD patients. Our study serves as first
indicator to point out effect of IFNGR1 mutation to MAP susceptibility in CD patients and
more studies with bigger sample size should be done to establish its role in MAP infection.
MAP has been long suggested as causal agent of CD and this study explains how genetic
and infectious factors work together to bring about the etiology of CD and UC.
The incidence of heterozygous SNP’s is lower in IBD group, suggesting the recessive
pattern of the SNPs to show phenotypic effects. It could also suggest that heterozygous
variants might have a protective action against MAP infection unlike homozygous minor
variants which cause susceptibility.
Patients with presence of SNP are found to be more infected with MAP. This suggests that
defective

-IFN signaling pathways with IFNGR1 defects could be responsible for

immune system’s failure to defend MAP infection, hence the bacteria opportunity to
induce more inflammation and more damage inside the gastro-intestinal mucosa. Further
studies need to be done how IFNGR1 mutation affect

-IFN signaling pathways to affect

defense against intracellular infections such as MAP. Our study could be the initial
demonstration of a possible novel therapeutic target of IFNGR1 for CD patients and it
emphasizes the existing role of MAP infection in CD causation.

Measurement of IFNGR1 gene expression
The RT-PCR result for comparing IFNGR1 gene expression in IBD against healthy and
NIBD shows downregulation in IBD patients 1.4-fold (P = 0.07) compared to 1.2-fold of
NIBD (P = 0.32). This suggests the mechanism of SNPs in causing MAP susceptibility
could be through downregulation of gene expression, hence causing loss of functional
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receptors. When we classify them into SNP positive, negative groups and MAP positive,
negative group, we can clearly see that more downregulation is seen with SNP positive
patients, and MAP positive patients even among IBD patients. This is evidence that MAP
infection is accompanied by more severe downregulation in IBD patients, again
supporting the hypothesis that IFNGR1 gene dysfunction is playing a role in MAP
susceptibility and hence contributing of MAP’s role in the complex nature of initiation of
CD inflammatory process.

Measurement of IFNGR1 protein level in serum
The trend of downregulation in IFNGR1 gene expression is replicated by serum levels of
IFNGR1 proteins. IFNGR1 protein has two forms, cell surface forms and soluble forms.
Even though cell surface forms are the main function form, we measure soluble forms in
serum as an indirect indicator of IFNGR1 protein translation levels. As we can see in Table
7,8 and 9, IBD patients and NIBD patients are downregulated compared to healthy, and
MAP positive patients are downregulated more than MAP negative patients. For SNP
positive patients, there is no downregulation unless they are paired with MAP infection.
Even though sample size is too small (control = 15, IBD = 23 in total for IFNGR1 ELISA)
to show statistical significance, more studies are suggested to establish the statistical
significance and phenomenon of downregulation in IFNGR1 SNP positive and MAP
positive IBD patients. This data also indicate that even though soluble receptors amount
are not significantly reduced, their functionality might be impaired, or the effect is on cell
surface receptors but not on soluble receptors
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Measurement of -IFN protein level in serum
When we measured the serum -IFN protein levels back in 2005, serum levels were elevated in
IBD patients by 11.59-fold (P >0.1). When we repeated the experiment in 2017, surprisingly,
there is no elevation of -IFN in IBD patients anymore. We hypothesize that widespread use of
biologic agents in last decade plays an essential role in it. Apart from infliximab (Remicade)
which was approved in 1998 by FDA, all the other biologic agents were approved after 2006,
when our experiments were performed[41, 42]. Hence we can assume that biologic agents were
not accessible and easily available back in 2005. Thus -IFN levels in IBD patients were not
suppressed. In 2017, biologic agents become accessible and affordable, covered by health
insurances, and medical treatment for IBD improved in potency and application, hence IBD
patients would be under the influence of immunosuppressive, anti-inflammatory and biologic
agents to control their signs and symptom of IBD and to maintain their clinical remission[42].
Thus, we detect no difference in -IFN levels in IBD patients in 2017 anymore. While this
phenomenon highlights improvement of medical therapy in the treatment of IBD, it also
indicates that we need to exercise extra-caution in detecting cytokines in patients’ blood as well
as interpreting the data.

Detection of MAP infection
MAP infection is more common in NIBD group but the prevalence is highest in CD and UC. It
appears that patients with immune dysregulation like RA or Type 1 diabetes are more
predisposed to MAP infection, but IBD patients are much more common. Thus, in addition to
immune dysregulation, it is reasonable to consider that there are factors that predispose IBD
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patients to MAP infection. Seeing as IFNGR1 SNPs are more common in patients with MAP
infection, IFNGR1 is one of the susceptibility factors making IBD patients get infected.
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CHAPTER THREE: GENERAL DISCUSSION
Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) whose
etiology has been suggested as multifactorial. CD etiology is influenced by
immunodysregulation, genetic mutations and microbial infections. This study uncovers the role
of a novel IFNGR1 mutation that causes susceptibility to various infections in CD and links
Mycobacterim avium paratuberculosis infection to Crohn’s disease through IFNGR1 mutation
and its associated immune dysfunction. IFNGR1 single nucleotide poloymorphisms (SNP)
prevalence is higher in IBD patients, and those SNP positive patients are more susceptible to
MAP infection as evident by higher MAP infection rates in these patients. In addition, SNP
positive and MAP positive patients are more downregulated in the gene transcription as well as
translation into serum IFNGR1 protein. MAP infection is found in higher incidence in IBD
patients and retrospective studies showed that those MAP infected patients have more SNP’s
detected. Serum -IFN levels used to be elevated in IBD patients in 2005, hence suggesting the
mechanism of IFNGR1 mutation in initiating CD, but their levels flatten out in 2017, which
might be the effect of biologic agents which were in widespread use in the years after 2005. All
in all, the study highlights the presence of IFNGR1 mutation as well as MAP infection in IBD
patients and gives an insight into the mechanism of IFNGR1 SNP’s contribution to CD
inflammation. Further studies with larger sample size as well as cell and molecular studies need
to be done on this matter and we hope that IFNGR1 and MAP therapy will be the start of novel
therapeutic targets in helping CD patients maintain remission and eradication of disease.
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APPENDIX A: FIGURES
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Figure 1: Biological themes predicted by DNA microarray technique for differentially
expressed genes in IBD.
17% (5630 genes) were differentially expressed in both IBD disorders, which consists of 4
biological themes, cellular processes (38%), physiological processes (26%), intracellular genes
(18%) and metabolic genes (18%). (Figure obtained from Doctor Romero Claudia PhD thesis)
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Figure 2: (A) Probe Binding and primer extension in a Taqman SNP Genotyping assay (B)
Allelic discrimation is achieved by the selective annealing of matching probe and template
sequences, which generates an allele-specific (fluorescent dye-specific) signal.
Picture from Vega, F.M.D.L., et al., Assessment of two flexible and compatible SNP genotyping platforms: TaqMan® SNP Genotyping
Assays and the SNPlex™ Genotyping System. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2005.
573(1–2): p. 111-135
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Figure 3: Prevalence of homozygous minor alleles in CD, UC, healthy and NIBD subject groups
for various SNP’s
CD patients have higher incidence in rs1327474, rs2234711, rs7749390. Rs1327475 is not
detected in any of the samples. Rs3799488 is found only in CD patients. Rs7749390’s higher
incidence in CD is statistically significant (P<0.05)
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Figure 4: Prevalence of heterozygous alleles in CD, UC, healthy and NIBD subject groups for
various SNP’s
rs1327474 incidence is relatively similar in all groups. Rs1327475 is found only in healthy.
Rs2234711 and rs7749390 are more common in healthy and NIBD (P<0.05), suggesting their
protective role and recessive pattern of inheritance to take affect. Rs3799488 is of higher
incidence in healthy and NIBD.
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Figure 5: Prevalence of at least one minor homozygous SNP in patient groups
81.82% of CD patients and 66.67% of UC have at least one homozygous minor allele
compared to 21.88% of healthy and 47.37% of NIBD (P <0.05 in both CD and UC). This
shows CD and UC patients are more prone to have homozygous minor IFNGR1 SNPs,
hence more susceptible to MAP infection.
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Figure 6: Comparison of 2005 and 2017 serum IFN-gamma levels in both control and IBD
groups
In 2005, serum γ-IFN levels of IBD are 11.6-fold higher than control group. In 2017, serum γIFN levels of both IBD and control groups are not elevated anymore.

29

Figure 7: Detection of MAP in Healthy, NIBD, IBD groups
34.4% of IBD have MAP presence while only 12.5% of healthy and 18.8% of NIBD
have MAP detected (P<0.05). MAP infection is more common in IBD.
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Figure 8: Detection of at least one homozygous minor SNP in MAP infected subjects
81.8% of MAP positive IBD patients have underlying IFNGR1 homozygous minor SNP
while only 25% of MAP positive healthy and 33.3% of MAP positive NIBD have
underlying SNP (P<0.05).

31

APPENDIX B: TABLES
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Table 1: Genes differentially expressed in both CD and UC compared to healthy subjects:
A total of 7 genes’ expressions were different, consisting of 6 downregulated genes and 1
upregulated gene.
No.

GeneBank
Accession Number

1
2
3

W79396
AI262976
W93370

4
5
6
7

Gene Product

Variable
expression
Downregulated
Downregulated
Downregulated

AA463248
AA775616
AA682637

Zinc finger protein 211
Zinc finger protein 211
NKG2-A and NKG2-B type II
integral membrane protein
CD 160 antigen
Secreted phosphoprotein 1
Carbohydrate sulfotransferase 2

AI371874

Toll-like receptor 4

Upregulated
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Downregulated
Downregulated
Downregulated

Table 2: Genes that are differentially expressed in either CD or UC or both
8 genes are differentially expressed in either CD or UC
No
1
2
3
4
5
6
7

8

GeneBank
Gene Product
Accession Number
AA083407
Tripartite motif-containing
22 (TRIM22)
AA454646
Lymphotoxin-beta receptor
AA476221
Zinc finger protein 558
AI123732
EBV induced G protein
coupled receptor 2 (EBI2)
AA281497
Interferon gamma receptor 1
(IFNGR1)
AI298976
Lymphotactin precursor
(XCL1)
AA495985
Macrophage inflammatory
protein 1-alpha precursor
(MIP-1)
R47893
Macrophage inflammatory
protein 1-alpha precursor
(MIP-1)
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Expression in
CD
No change

Expression in
UC
Downregulated

No change
Downregulated
Downregulated

Upregulated
No change
No change

Downregulated

No change

Downregulated

No change

Downregulated

Upregulated

Downregulated

Upregulated

Table 3: Five SNPs that are investigated in this study along with their location, microbes that they cause susceptibility to, Assay ID
and context sequence
Due to proprietary reasons from Thermo Fisher Scientific, we cannot provide the forward and reverse primer sequences.
However, we can provide the assay ID number and context sequence for each SNP assay. rs# = reference SNP number
No.

SNP

Location on
Gene

1

rs1327474

UTR 5 promotor

2

rs1327475

Intron

3

rs2234711

4

rs7749390

Transcription
factor AP4
binding site
Extron/Intron
splice site

5

rs3799488

Intron

Associated condition and
microbial infection that are found
to be susceptible
 Mycobacterium
tuberculosis
 Helicobacter pylori
 Mendelian susceptablity
to mycobacterial
disease
 Schistomsoma
mansoni
 Mycobacterium
tuberculosis 
 Leishmaniasis
 Mycobacterium
tuberculosis 
 Leishmaniasis
 Ezema herpeticum caused
by Herpes simplex virus
 Mycobacterium
tuberculosis 
 leishmaniasis
 Ezema herpeticum caused
by Herpes simplex virus
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Assay ID

Context sequence

C___2523634_10

GCAATTCAGTGTCAAATCAGT
TTAT[C/T]AGGCAGCCTCTCAT
GAAGAG GTCTG

C___7578576_10

AGACTATTTTCTGGTGACTTCA
AAA[A/G]CATCTGCTTCAGGT
AATGTTT CCTG
CGAGCGCCTGCGGGACCAGC
CCAGC[A/G]CTGCCCTCCAGC
CCCGGCCT TACGT

C__11693991_10

C__25647357_10

CGACCCGGCCGCAGCCCTGCC
GCGA[A/G]CGACGGTACCTGA
GGACGG CCCCAG

C__25647358_10

TAGCACTTCTTACCACAGAGA
TCTA[C/T]GGGGAGAAAAATTG
ATTAAA GATAA

Table 4: Gene expression levels studies among healthy, NIBD and IBD groups
IBD patients are 1.4fold downregulated (P =0.07) while NIBD patients are 1.2-fold
downregulated (P=0.32).
Fold change

P
values

Healthy (N = 30)

Mean of RT-PCR
2^(-∆CT)*1000
Mean ± 95% CI
5.3 ± 2.4

NIBD (N=14)

4.5 ± 0.9

-1.2 fold

0.32

IBD (N = 54)

3.8 ± 0.9

-1.4 fold

0.07

Samples
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Table 5: Gene expression level studies comparing MAP positive and MAP negative samples
among the same group, and comparison of samples with both MAP and SNP with MAP
negative group.
MAP positivity alone is associated with 1 7-fold downregulation (P =0.06) and MAP and SNP
positivity together is also associated with 1.7-fold downregulation (P=0.08).
Groups

MAP
Positive
(Mean ± 95% CI )

MAP
Negative

Fold
change

P
value

Healthy

1.4 ± 1.1
(N = 3)

3.6 ± 2.1
(N = 21)

-2.6fold

0.2

4.7 ± 0.8
(N = 11)
5.8 ± 2.4
(N = 14)

-1.2 fold

0.2

-1.7 fold

0.06

-1.7 fold

0.08

NIBD

3.8 ± 5.9
(N = 3)
3.3 ± 1.8
IBD
(N = 10)
IBD
3.4 ± 1.9
(MAP + SNP) (N = 8)
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Table 6: Gene expression level studies comparing SNP positive and SNP negative samples
among the same group.
SNP positivity causes downregulation of 1.5-fold in IBD group (P = 0.1)

SNP positive

SNP
negative

Fold
change

P value

7.6 ± 7.3

4.8 ± 2.6

1.6-fold

0.2

(N = 6)

(N = 24)

NIBD

5.0 ± 0.9
(N = 7)

4.1 ± 1.7
(N = 7)

1.2-fold

0.1

IBD

4.6 ± 1.6
(N = 19)

6.9 ± 7.7
(N = 4)

-1.5-fold

0.1

Healthy
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Table 7: Serum IFNGR1 protein levels in healthy, NIBD and IBD groups.
IBD and NIBD groups are 1.53-fold (P =0.15) and 1.61-fold (P =0.21) lower than normal.
Sample

Fold change

Healthy (N=6)

IFNGR1 serum
(pg/ml)
Mean ± 95% CI
810.8 ± 1024.5

NIBD (N=9)

502.7 ± 263.2

-1.61-fold

0.21

IBD (N=24)

530.3 ± 190.5

-1.53-fold

0.15
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P value

Table 8: Serum IFNGR1 protein levels compared in MAP positive and MAP negative patients
Sample

Healthy
NIBD
IBD

MAP positive
Mean ± 95% CI
520.6
(N =1)
465.1 ± 466
(N = 3)
419.7± 141.8
(N =8)

MAP negative

365 ± 208.6
(N = 4)
478.9 ± 358.9
(N =7)
573.5 ± 333.9
(N =13)

Fold
change

P value

-1.4

.
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-1.0

0.5

-1.4

0.5

Table 9: Serum IFNGR1 protein levels in patients with existence of MAP and SNP together
Sample

MAP + SNP
Mean ± 95% CI

Fold
change

Healthy

520.6 (N = 1)

-1.42

NIBD

223.2 (N = 1)

-2.14

IBD

377.7 ± 112.5 (N = 8)

-1.51
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P value

0.2

Table 10: Serum IFNGR1 protein levels in SNP positive and SNP negative patients
Sample
Healthy
NIBD
IBD

SNP positive

Fold
change

SNP negative

P value

440.7 ± 369.9
(N=3)
476.1 ± 360.7
(N= 7)

329.2 ± 703.2
(N = 3)
471.7 ± 440.8
(N = 3)

1.3

0.2

1.0

0.98

512.7 ± 213.6
(N=20)

454.4
(N =2)

1.1

0.4
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Table 11: Presence of MAP in different types of IFNGR1 homozygous minor SNP.
In rs1327474, 1 out of 5 IBD patients with SNP (20%)) has MAP infection, compared to 0 out of
1 in healthy (0%). Rs1327475 is not detected in any of samples. Among rs2234711 positive
samples, 71.4% of IBD patients have MAP infection compared to 0% in healthy and NIBD.
Rs7749390 SNP positive samples have 16.7% of healthy, 33.3% of NIBD and 26.7% of IBD
having MAP detected. Rs3799488 is detected only in IBD and 50% of them has MAP presence.
SNP

Healthy
(N = 32)

NIBD
(N = 19)

IBD
(N = 28)

P value

rs1327474

0/1
(0%)

----

1/5
(20%)

0.62

rs1327475

---

----

---

---

rs2234711

0/5
(0%)

0/3
(0%)

5/7
(71.4%)

0.013*

rs7749390

1/6
(16.7%)

2/6
(33.3%)

4/15
(26.7%)

0.62

rs3799488

---

---

1/2
(50%)

---
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